Cargando…
Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation
Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir and remdesivir in spiked human plasma. The UV...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273576/ https://www.ncbi.nlm.nih.gov/pubmed/37328879 http://dx.doi.org/10.1186/s13065-023-00967-6 |
_version_ | 1785059689439952896 |
---|---|
author | Batubara, Afnan S. Abdelazim, Ahmed H. Almrasy, Ahmed A. Gamal, Mohammed Ramzy, Sherif |
author_facet | Batubara, Afnan S. Abdelazim, Ahmed H. Almrasy, Ahmed A. Gamal, Mohammed Ramzy, Sherif |
author_sort | Batubara, Afnan S. |
collection | PubMed |
description | Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir and remdesivir in spiked human plasma. The UV absorption spectra of favipiravir and remdesivir have shown some overlap, making simultaneous determination difficult. Due to the considerable overlap, two ratio spectra manipulating spectrophotometric methods, namely, ratio difference and the first derivative of ratio spectra, enabled the determination of favipiravir and remdesivir in their pure forms and spiked plasma. The ratio spectra of favipiravir and remdesivir were derived by dividing the spectra of each drug by the suitable spectrum of another drug as a divisor to get the ratio spectra. Favipiravir was determined by calculating the difference between 222 and 256 nm of the derived ratio spectra, while calculating the difference between 247 and 271 nm of the derived ratio spectra enabled the determination of remdesivir. Moreover, the ratio spectra of every drug were transformed to the first order derivative using ∆λ = 4 and a scaling factor of 100. The first-order derivative amplitude values at 228 and 251.20 nm enabled the determination of favipiravir and remdesivir, respectively. Regarding the pharmacokinetic profile of favipiravir (C(max) 4.43 µg/mL) and remdesivir (C(max) 3027 ng/mL), the proposed methods have been successfully applied to the spectrophotometric determination of favipiravir and remdesivir in plasma matrix. Additionally, the greenness of the described methods was evaluated using three metrics systems: the national environmental method index, the analytical eco-scale, and the analytical greenness metric. The results demonstrated that the described models were in accordance with the environmental characteristics. |
format | Online Article Text |
id | pubmed-10273576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-102735762023-06-17 Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation Batubara, Afnan S. Abdelazim, Ahmed H. Almrasy, Ahmed A. Gamal, Mohammed Ramzy, Sherif BMC Chem Research Favipiravir and remdesivir have been included in the COVID-19 treatment guidelines panel of several countries. The main objective of the current work is to develop the first validated green spectrophotometric methods for the determination of favipiravir and remdesivir in spiked human plasma. The UV absorption spectra of favipiravir and remdesivir have shown some overlap, making simultaneous determination difficult. Due to the considerable overlap, two ratio spectra manipulating spectrophotometric methods, namely, ratio difference and the first derivative of ratio spectra, enabled the determination of favipiravir and remdesivir in their pure forms and spiked plasma. The ratio spectra of favipiravir and remdesivir were derived by dividing the spectra of each drug by the suitable spectrum of another drug as a divisor to get the ratio spectra. Favipiravir was determined by calculating the difference between 222 and 256 nm of the derived ratio spectra, while calculating the difference between 247 and 271 nm of the derived ratio spectra enabled the determination of remdesivir. Moreover, the ratio spectra of every drug were transformed to the first order derivative using ∆λ = 4 and a scaling factor of 100. The first-order derivative amplitude values at 228 and 251.20 nm enabled the determination of favipiravir and remdesivir, respectively. Regarding the pharmacokinetic profile of favipiravir (C(max) 4.43 µg/mL) and remdesivir (C(max) 3027 ng/mL), the proposed methods have been successfully applied to the spectrophotometric determination of favipiravir and remdesivir in plasma matrix. Additionally, the greenness of the described methods was evaluated using three metrics systems: the national environmental method index, the analytical eco-scale, and the analytical greenness metric. The results demonstrated that the described models were in accordance with the environmental characteristics. Springer International Publishing 2023-06-16 /pmc/articles/PMC10273576/ /pubmed/37328879 http://dx.doi.org/10.1186/s13065-023-00967-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Batubara, Afnan S. Abdelazim, Ahmed H. Almrasy, Ahmed A. Gamal, Mohammed Ramzy, Sherif Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation |
title | Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation |
title_full | Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation |
title_fullStr | Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation |
title_full_unstemmed | Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation |
title_short | Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation |
title_sort | quantitative analysis of two covid-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273576/ https://www.ncbi.nlm.nih.gov/pubmed/37328879 http://dx.doi.org/10.1186/s13065-023-00967-6 |
work_keys_str_mv | AT batubaraafnans quantitativeanalysisoftwocovid19antiviralagentsfavipiravirandremdesivirinspikedhumanplasmausingspectrophotometricmethodsgreennessevaluation AT abdelazimahmedh quantitativeanalysisoftwocovid19antiviralagentsfavipiravirandremdesivirinspikedhumanplasmausingspectrophotometricmethodsgreennessevaluation AT almrasyahmeda quantitativeanalysisoftwocovid19antiviralagentsfavipiravirandremdesivirinspikedhumanplasmausingspectrophotometricmethodsgreennessevaluation AT gamalmohammed quantitativeanalysisoftwocovid19antiviralagentsfavipiravirandremdesivirinspikedhumanplasmausingspectrophotometricmethodsgreennessevaluation AT ramzysherif quantitativeanalysisoftwocovid19antiviralagentsfavipiravirandremdesivirinspikedhumanplasmausingspectrophotometricmethodsgreennessevaluation |